Chinese expert consensus on lung and thymus neuroendocrine neoplasms.
10.3760/cma.j.cn112152-20210719-00522
- VernacularTitle:中国肺和胸腺神经内分泌肿瘤专家共识
- Collective Name:Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
- Publication Type:Journal Article
- Keywords:
Consensus;
Diagnosis;
Lung and thymus neuroendocrine neoplasms;
Treatment
- MeSH:
Carcinoid Tumor;
China;
Consensus;
Humans;
Lung;
Neuroendocrine Tumors/therapy*
- From:
Chinese Journal of Oncology
2021;43(10):989-1000
- CountryChina
- Language:Chinese
-
Abstract:
Lung and thymus neuroendocrine neoplasms (NENs) are rare tumors. According to the fifth edition of the World Health Organization classification of thoracic tumors published in 2021, lung and thymus NENs include typical carcinoids, atypical carcinoids, large cell neuroendocrine carcinomas, and small cell carcinomas. Although the incidence of lung and thymus NENs has gradually increased in recent years, there is a lack of randomized controlled clinical study results to guide clinical practice. The treatment of early-stage lung and thymus NENs is complete surgical resection, and the treatment methods for unresectable advanced diseases include different medical treatments, peptide receptor radionuclide therapy, and local therapy. To improve the standardization of diagnosis and treatment of lung and thymus NENs in China, the Expert Committee of Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology developed the expert consensus after multidisciplinary expert discussions based on existing clinical study evidences and guidelines from different neuroendocrine tumor societies. The contents of the consensus cover the epidemiology, diagnosis, pathological classification, staging, treatment and follow-up of lung and thymus NENs (except small cell lung cancer).
